Retatrutide
Description
A highly advanced, single-molecule triple hormone receptor agonist representing the cutting edge of metabolic research. Retatrutide is the first compound to simultaneously engage three key metabolic pathways, making it a subject of intense scientific interest in obesity and metabolic syndrome research.
Mechanism of Action
Targets GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), and Glucagon receptors simultaneously. This triple-agonist mechanism regulates appetite through central nervous system signaling, delays gastric emptying to promote satiety, and increases energy expenditure via glucagon-mediated thermogenesis, leading to significant metabolic regulation and weight management in research models.
Research Protocols
In clinical research settings, initialized at 2mg once weekly for 4 weeks via subcutaneous injection, titrating upwards by 2mg increments every 4 weeks up to a maximum of 8mg to 12mg weekly. This gradual titration protocol is designed to optimize receptor engagement while minimizing gastrointestinal adaptation effects.